- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
FDA OKs Sotatercept, Merck's Pulmonary Arterial Hypertension Drug
Merck is pricing the new drug at $14,000 per vial. The annual cost for most patients eligible for the drug will be approximately $240,000.
The FDA has approved sotatercept, a new treatment for pulmonary arterial hypertension.
Merck is selling the drug under the brand name Winrevair.
Merck is pricing the drug at $14,000 per vial, before any rebates or discounts.
Merck says that approximately two-thirds of patients will need to be treated with a vial every three weeks. At that frequency, the annual cost would add to up approximately $240,000.
Pulmonary arterial hypertension (PAH) is a characterized by high blood pressure in the arteries of the lungs. PAH usually affects women between the ages of 30 and 60, according to the National Organization of Rare Disorders.
Today’s approval came just a day after the FDA approved Opsynvi for PAH. A Johnson & Johnson product, Opsynvi combines macitanten and tadalafil, which are commonly prescribed to treat PAH. Tadalafil is also an erectile dysfunction drug that is sold under the brand name Cialis.
Merck said in a press release today that Winrevair would be available from select specialty pharmacies by the end of next month,
The drug is administered by subcutaneous (under the skin) injection.The Merck press release says it can be administered by patients or caregivers with guidance, training and follow-up from a healthcare provider.
This is a developing story.
FDA Update for Week of April 22, 2024: Second Gene Therapy for Hemophilia B
April 27th 2024This week, the FDA has approved several products, including Beqvez, the second gene therapy hemophilia B; Ojemda for children with brain tumors; an additional indication for Lutathera for adolescents with neuroendocrine tumors; and a bladder cancer immunotherapy. The agency has also issued a complete response letter for pz-cel to treat epidermolysis bullosa.
Read More
DC Roundtable: Patrick Cooney of The Federal Group Drops the Latest on PBM Legislation in Washington
April 11th 2024In this episode of "DC Roundtable," Peter Wehrwein, managing editor of Managed Healthcare Executive, spoke with Patrick Cooney, president of The Federal Group, a lobbying and strategic planning firm in Washington, D.C., about recent developments in Washington concerning PBMs.
Listen
